One of the drug cocktails now in preclinical development for Ebola, ZMapp, has been used for a small group of emergency cases. And now two Scripps investigators have come up with a 3-D model to show where its three antibodies stick to the virus, pointing to new and better therapies as well as informing work on other such cocktail therapies.
The Geneva Foundation, along with partner BioFactura, received a grant of more than $3 million from the U.S. National Institutes of Health to develop an antibody drug to combat the Sudan strain of the ebolavirus.
The drug, a combination of three monoclonal antibodies, has so far been given to 7 patients in the current Ebola outbreak.
A novel biomarker could make it easier for physicians to diagnose rheumatoid arthritis early, thereby improving patients' prospects. The best results come when conventional antibody testing is combined with the new biomarker.
German drug developer MorphoSys is pairing up with Emergent BioSolutions to get its hands on an early-stage prostate cancer treatment, signing a deal worth up to $183 million for a promising antibody.
For William Strohl, the new head of Janssen's Biotechnology Center of Excellence, the future of drug R&D involves novel targets, "fit-for-purpose" antibodies and lots of collaborations.
The Scripps Research Institute has landed a $13 million grant from the National Institute of Allergy and Infectious Diseases to advance antibodies toward the development of an HIV vaccine. Meanwhile, another team of researchers at the University of Nebraska-Lincoln has won nearly $2 million for its experimental HIV vaccine.
In a discovery that could put a vaccine for malaria closer in sight, scientists have linked a protein to an essential function in malaria-causing parasites that enables them to escape from inside red blood cells and infect the rest of the body.
Tesaro is making a move into the hot cancer immunotherapy field, paying $17 million upfront and offering milestones worth hundreds of millions more to work with AnaptysBio on a portfolio of antibodies that could be used in combination with its own pipeline drugs. And while one of the targets is PD-1, a popular subject in a field now dominated by Bristol-Myers Squibb and Merck, a pair of less familiar targets is also included in the package.
A team of U.S. and South African researchers has identified and cloned an antibody that targets one of the few unchanging regions of HIV.